| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
IC50: 0.45 μM (ABCG2/BCRP), 2.17 μM (ABCB1)[1]
ABCG2 (BCRP), ABCB1 (P-glycoprotein) |
|---|---|
| ln Vitro |
Efflux inhibitor-1 is a pyrazolo[1,5-a]pyrimidine efflux inhibitor with IC₅0 values of 0.45 uM (ABCG2/BCRP) and 2.17 uM (ABCB1). It selectively targets ABCG2 over ABCB1. By blocking drug efflux, it reverses multidrug resistance in cancer cells, enhancing the cytotoxicity of ABCG2/ABCB1 substrate drugs (e.g., doxorubicin, mitoxantrone).
|
| ln Vivo |
No detailed in vivo activity data for Efflux inhibitor-1 has been reported. As an MDR reversal agent, it is expected to enhance the efficacy of chemotherapeutic drugs in mouse xenograft models of drug‑resistant cancer. Co‑administration with substrate chemotherapeutics would be required to demonstrate in vivo efficacy.
|
| Enzyme Assay |
For ABCG2/BCRP efflux activity assays, membrane vesicles from cells overexpressing ABCG2 or ABCB1 are incubated with a fluorescent substrate (e.g., Hoechst 33342 or pheophorbide A) and various concentrations of efflux inhibitor-1 (0.01‑10 uM). Substrate accumulation is measured by fluorescence. IC₅0 values are calculated.
|
| Cell Assay |
Efflux inhibitor-1 is dissolved in DMSO and diluted in cell culture media (final DMSO ≤0.1%). ABCG2/BCRP- or ABCB1-overexpressing cancer cells (e.g., HEK293/R2, MCF-7/ADR) are treated with efflux inhibitor-1 (0.01‑10 uM) in the presence or absence of a substrate chemotherapeutic (e.g., doxorubicin). Intracellular drug accumulation is measured by fluorescence or LC‑MS/MS. Cell viability is assessed by MTT or CellTiter-Glo assays.
|
| Animal Protocol |
No detailed in vivo protocol for efflux inhibitor-1 has been reported. For MDR reversal studies, the compound would be formulated in a suitable vehicle (e.g., 10% DMSO, 40% PEG400, 5% Tween 80) and administered orally or intraperitoneally to mice bearing drug‑resistant tumor xenografts, either alone or in combination with a substrate chemotherapeutic (e.g., doxorubicin). Efficacy would be assessed by tumor growth inhibition.
|
| ADME/Pharmacokinetics |
No PK data for efflux inhibitor-1 has been reported. As a small‑molecule efflux inhibitor, it is expected to have moderate oral bioavailability and sufficient plasma exposure to inhibit ABCG2/BCRP in tumors. Detailed parameters such as half‑life, Cmax, and clearance are not publicly available.
|
| Toxicity/Toxicokinetics |
No toxicity data for efflux inhibitor-1 has been reported. As an ABCG2/ABCB1 inhibitor, potential toxicities may include increased systemic exposure to endogenous ABCG2/ABCB1 substrates and chemotherapeutic agents when co‑administered. No toxicology studies have been published.
|
| References | |
| Additional Infomation |
3-Furanyl-[4-[2-(2-methoxyphenyl)-5-phenyl-7-pyrazolo[1,5-a]pyrimidinyl]-1-piperazinyl] methyl ketone is a pyrimidine compound.
Efflux inhibitor-1 (compound 2; CAS: 1776055-29-8; formula: C2₈H2₅N₅O3; MW: 479.53) is a selective ABCG2/BCRP efflux inhibitor that reverses multidrug resistance in cancer cells. It is a valuable research tool for studying MDR mechanisms and evaluating combination therapy strategies. No clinical trials or regulatory approvals have been reported. |
| Molecular Formula |
C28H25N5O3
|
|---|---|
| Molecular Weight |
479.529805898666
|
| Exact Mass |
479.195
|
| CAS # |
1776055-29-8
|
| PubChem CID |
44640183
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
36
|
| Complexity |
741
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C1C=COC=1)(N1CCN(C2N3N=C(C4=CC=CC=C4OC)C=C3N=C(C3=CC=CC=C3)C=2)CC1)=O
|
| InChi Key |
SFNWNSAJWDYPJC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C28H25N5O3/c1-35-25-10-6-5-9-22(25)24-17-26-29-23(20-7-3-2-4-8-20)18-27(33(26)30-24)31-12-14-32(15-13-31)28(34)21-11-16-36-19-21/h2-11,16-19H,12-15H2,1H3
|
| Chemical Name |
furan-3-yl-[4-[2-(2-methoxyphenyl)-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl]piperazin-1-yl]methanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (104.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0854 mL | 10.4269 mL | 20.8538 mL | |
| 5 mM | 0.4171 mL | 2.0854 mL | 4.1708 mL | |
| 10 mM | 0.2085 mL | 1.0427 mL | 2.0854 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
